Hepatitis B vaccine recombinant - Crucell

Drug Profile

Hepatitis B vaccine recombinant - Crucell

Alternative Names: AgB; Biovac-B; Hepavax-Gene; Hepavax-Gene TF; Supervax

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Crucell; Dynavax Dusseldorf
  • Developer Crucell; Dynavax Dusseldorf; Laboratorio Pablo Cassara
  • Class Hepatitis B vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis B

Most Recent Events

  • 01 Nov 2013 Crucell completes a phase III trial in Hepatitis B prevention in China (NCT01349283)
  • 07 Jul 2011 Crucell initiates enrolment in a phase III trial in Hepatitis B pervention in China (NCT01349283)
  • 22 Feb 2011 Crucell has been acquired by Johnson & Johnson
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top